Generics & Biosimilars
GLP-1 drugs have revolutionized pharma, becoming mainstream and generating billions for suppliers. As patent expiries near, generics manufacturers are preparing to enter the market. The US biosimilars market, nearing its first decade, saw a busy 2024 with Amgen's surprise launch of an Eylea rival and other first-time approvals. Competition for Stelara is expected to begin in early 2025.
Our latest ranking of the world’s leading off-patent companies reflects a fairly stable leading group this year – but this belies the significant evolutions seen for major generics and biosimilars players over the past 12 months.
As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024. Meanwhile, competition to Stelara is waiting in the wings from the start of 2025.
GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.
The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.